Pharmacyclics v. BeiGene: BTK Inhibitor Patent Invalidated, Dismissed With Prejudice
Pharmacyclics LLC asserted US Patent No. 11,672,803 — covering use of Bruton’s tyrosine kinase (BTK) inhibitors — against BeiGene in Delaware. After BeiGene secured a PTAB Final Written Decision invalidating all asserted claims in post-grant review, the parties voluntarily dismissed the case with prejudice across 840 days of proceedings.
PTAB Invalidity Win Forces Pharmacyclics to Abandon BTK Patent Suit
On June 13, 2023, Pharmacyclics LLC filed suit in the District of Delaware against BeiGene USA, Inc. and BeiGene, Ltd. (now BeOne Medicines), asserting infringement of US11,672,803, which covers the use of Bruton’s tyrosine kinase (BTK) inhibitors. BTK inhibition is a validated mechanism in hematologic oncology, and the patent sits at the commercial intersection of Pharmacyclics’ ibrutinib franchise and BeiGene’s competing zanubrutinib (Brukinsa) program.
BeiGene answered in August 2023, counterclaiming for invalidity and non-infringement, and simultaneously filed a petition for post-grant review before the PTAB. The district court action was stayed by agreement from October 2023 pending the PGR outcome. On April 29, 2025, the PTAB issued a Final Written Decision finding all asserted claims of the ‘803 Patent unpatentable. Pharmacyclics sought Director Review, which was denied on July 17, 2025. Pharmacyclics then declined to appeal, and the parties stipulated to dismissal with prejudice under Fed. R. Civ. P. 41.
The 840-day duration reflects a litigation arc shaped almost entirely by the PTAB track rather than district court merits proceedings. The stay strategy — agreed by both sides — is consistent with a calculated defense: BeiGene avoided costly district court discovery while prosecuting an administrative invalidity route that ultimately eliminated the asserted claims entirely. Pharmacyclics’ decision not to appeal the Final Written Decision to the Federal Circuit, despite denial of Director Review, suggests the record on unpatentability was sufficiently adverse to make an appeal commercially unattractive.
Filing to Voluntary dismissal in 840 days
840 days — from filing to dismissal, spanning a district court stay and full PTAB PGR cycle
Dismissed with prejudice after PTAB invalidates all claims: what it means
Voluntary dismissal with prejudice follows PTAB invalidation
Under Fed. R. Civ. P. 41(a)(1)(A)(i)-(ii) and (c), the parties jointly noticed and stipulated to voluntary dismissal with prejudice. ‘With prejudice’ means Pharmacyclics is permanently barred from reasserting the same claims of the ‘803 Patent against BeiGene in any future action. The dismissal is a direct consequence of PTAB finding all asserted claims unpatentable — there was no remaining patent right to enforce.
Dismissal with prejudice — Rule 41Pharmacyclics loses patent weapon and re-assertion rights
The ‘803 Patent’s asserted claims were found unpatentable by PTAB. Pharmacyclics’ decision not to appeal to the Federal Circuit — despite the Director Review denial — effectively accepts that outcome as final. The with-prejudice dismissal eliminates any district court path back against BeiGene on these claims. Pharmacyclics retains other IP assets in its BTK portfolio, but loses this specific enforcement avenue permanently.
Patent claims cancelled — no appealBeiGene secures invalidity via PGR without district court trial
BeiGene’s PGR petition strategy proved decisive: it eliminated all asserted claims through PTAB before the district court stay was lifted, avoiding full merits litigation. The with-prejudice dismissal protects BeiGene from any future reassertion of the same claims. BeiGene’s zanubrutinib (Brukinsa) programme faces no further threat from the ‘803 Patent’s asserted claims, providing commercial clearance in the BTK inhibitor space for this specific patent.
Full invalidity — commercial clearanceBTK inhibitor IP landscape: PGR as a competitive weapon
This case illustrates the potency of post-grant review as a competitive tool in biopharma patent disputes. A well-timed PGR petition, combined with a district court stay, can neutralise a patent assertion before it reaches trial. For other BTK inhibitor developers, the invalidation of the ‘803 Patent’s asserted claims may reduce one barrier to entry, though Pharmacyclics holds a broader portfolio. Competitors should audit remaining Pharmacyclics BTK patents before drawing conclusions on FTO.
PGR strategy validatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pharmacyclics, LLC | Company | Biopharmaceutical company — holder of US11672803 covering BTK inhibitor useSearch in Eureka ↗ |
| Defendant | BeiGene USA, Inc. | Company | BeiGene USA, Inc. and BeiGene, Ltd. (BeOne Medicines) — developer of zanubrutinib (Brukinsa)Search in Eureka ↗ |
| Co-Defendant | BeiGene, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Pharmacyclics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Pharmacyclics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pharmacyclics, LLCSearch in Eureka ↗ |
| Defendant counsel | Anish R. Desai | Attorney | Counsel for BeiGene USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher J. Mandernach | Attorney | Counsel for BeiGene USA, Inc.Search in Eureka ↗ |
| Defendant counsel | David E. Wilks | Attorney | Counsel for BeiGene USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Donald C. Vavala , III | Attorney | Counsel for BeiGene USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Elizabeth S. Weiswasser | Attorney | Counsel for BeiGene USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Priyata Y. Patel | Attorney | Counsel for BeiGene USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Seth R. Bowers | Attorney | Counsel for BeiGene USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Wilks Law LLC | Law Firm | Representing BeiGene USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Williams & Connolly LLP – Washington | Law Firm | Representing BeiGene USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal stipulation is notable for what it documents procedurally: PTAB’s Final Written Decision found all asserted claims of the ‘803 Patent unpatentable, Director Review was denied, and Pharmacyclics expressly declined to appeal. The with-prejudice election under Rule 41(a)(1)(A)(i)-(ii) and (c) reflects a negotiated finality — BeiGene obtains permanent protection from reassertion of these claims, while Pharmacyclics avoids further litigation cost on a patent whose claims PTAB had already cancelled. The own-costs arrangement is consistent with a case resolved on administrative grounds rather than district court adjudication.
US11672803 — Use of Bruton’s Tyrosine Kinase (BTK) Inhibitors
US11,672,803 (application number US16/926,280) covers the use of Bruton’s tyrosine kinase (BTK) inhibitors — a mechanistic class central to the treatment of B-cell malignancies including chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma. BTK inhibition has become one of the most commercially significant mechanisms in haematological oncology, with ibrutinib (AbbVie/Pharmacyclics) and zanubrutinib (BeiGene) as leading market participants. As a utility patent directed to use, the claims asserted were targeted at BeiGene’s clinical and commercial activity rather than the compound itself.
The strategic value of the ‘803 Patent lay in its potential to constrain BeiGene’s zanubrutinib (Brukinsa) programme — a next-generation BTK inhibitor that has taken significant market share from ibrutinib in multiple oncology indications. PTAB’s decision to find all asserted claims unpatentable removes this enforcement tool from Pharmacyclics’ arsenal. For the broader BTK inhibitor sector, this outcome may modestly ease the patent thicket around BTK-directed therapeutics, though Pharmacyclics and AbbVie hold additional patents that continue to define the competitive IP boundary.
Should you run an FTO against US11672803 and related BTK inhibitor patents?
For R&D teams and product managers developing BTK inhibitor therapies, this case confirms that the ‘803 Patent’s asserted claims have been found unpatentable by PTAB and will not be reasserted against BeiGene. However, this does not constitute a clean freedom-to-operate signal for the broader BTK inhibitor space. Pharmacyclics and AbbVie maintain a layered patent portfolio covering BTK inhibitor compounds, formulations, dosing regimens, and combination therapies — any of which could be asserted against new market entrants or competing programmes.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map the full Pharmacyclics and AbbVie BTK patent estate, identify claim scope relevant to your specific compound or method, and track post-grant proceedings across the portfolio. Rather than relying on a single case outcome, Eureka provides a systematic landscape view — essential before initiating clinical development, seeking regulatory approval, or entering commercial supply agreements in any BTK-directed therapeutic programme.
Run a freedom-to-operate analysis on US11672803B2 to assess your product’s exposure
Run FTO in Eureka →Similar BTK Inhibitor Patent Cases in Delaware District Court
Other BTK inhibitor and kinase-directed patent disputes before the Delaware District Court, including related Pharmacyclics and AbbVie enforcement actions.
What this case signals for the BTK inhibitor IP landscape
BeiGene’s PGR-first strategy reset the competitive dynamics in BTK inhibitor patent enforcement. Here is what IP teams should take away.
PGR petitions can resolve biopharma patent suits before district court trial
BeiGene filed its PGR petition shortly after answering, secured a stay, and ultimately obtained invalidation of all asserted claims — without ever proceeding to district court merits. For defendants facing late-issued patents (post-grant review window open), this case is a strong precedent for leading with PTAB rather than district court defences.
With-prejudice dismissal locks out reassertion — verify your exposure scope
The dismissal is confined to the asserted claims of US11,672,803. Pharmacyclics retains a substantial BTK-related portfolio. Companies operating in the BTK inhibitor space should not treat this outcome as blanket clearance — a targeted FTO analysis across Pharmacyclics’ remaining patents remains essential before product launch or expansion.
Pharmacyclics v BeiGene — key questions answered
PTAB issued a Final Written Decision on April 29, 2025 finding all asserted claims of US11,672,803 unpatentable in a post-grant review proceeding filed by BeiGene. Pharmacyclics’ request for Director Review was denied on July 17, 2025. Pharmacyclics then declined to appeal to the Federal Circuit, and the parties voluntarily dismissed the district court action with prejudice.
The parties agreed to stay proceedings from October 12, 2023 — approximately four months after filing — pending the outcome of BeiGene’s PTAB post-grant review petition and any subsequent appeals. This agreed stay is consistent with a common Delaware practice of pausing district court litigation when a parallel PTAB proceeding offers a potentially dispositive administrative challenge to patent validity.
Dismissal with prejudice under Fed. R. Civ. P. 41 permanently bars Pharmacyclics from reasserting the same claims of the ‘803 Patent against BeiGene in any future action. Because PTAB also found those claims unpatentable, the claims face a double bar: they are both cancelled administratively and precluded from re-litigation in district court.
The PTAB’s Final Written Decision in the PGR proceeding renders the invalidated claims unpatentable as a matter of USPTO administrative record. This provides third parties with a strong prior art and unpatentability record. However, it does not eliminate Pharmacyclics’ broader BTK patent portfolio, and other BTK inhibitor developers should conduct independent FTO analysis rather than relying solely on this outcome.
A post-grant review is a PTAB proceeding available within nine months of a patent’s grant date, allowing any party to challenge patent validity on any statutory ground. BeiGene filed a PGR petition against US11,672,803. PTAB instituted the proceeding, conducted a full review, and issued a Final Written Decision on April 29, 2025 finding all asserted claims unpatentable — effectively cancelling those claims and eliminating the foundation of Pharmacyclics’ district court infringement suit.
PatSnap Eureka searches patents and litigation data to answer instantly.